Therapeutic effect evaluation of Fu-Zheng Jie-Du Xiao-Ji approach in the treatment of hepatitis B virus-related hepatocellular carcinoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033941

Enrollment

Unknown

Registered

2020-06-18

Start date

2015-01-01

Completion date

Unknown

Last updated

2020-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

Integrated Chinese and Western medicine group:Fuzheng jiedu jixiaoji prescription and comprehensive treatment of Western medicine

control group:Comprehensive treatment of Western medicine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) the primary liver cancer diagnosis standard; (2) Chronic hepatitis B virus infection; (3) Male or female aged 18-65 years; (4) Deficiency of qi and Yin and accumulation of poison and blood stasis; (5) Sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Liver cancer patients with metastasis from other tumors; (2) Patients with other malignant tumors; (3) Patients with serious heart and kidney complications or other primary diseases; Psychopaths; (4) Upper gastrointestinal bleeding; (5) Hepatorenal syndrome; (6) Pregnant or lactating women; (7) Patients cannot cooperate.

Design outcomes

Primary

Measure	Time frame
Overall survival of 48 weeks;Medium survival time;Remission rate of solid tumors;AFP level;Liver function;Child-Pugh class;Complication rate;TCM syndrome score;	—

Countries

China

Contacts

Public ContactXianbo Wang

Beijing Ditan Hospital, Capital Medical University

wangxianbo638@163.com+86 13011001598

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026